Poly Medicure share price, P/E, ROE & financials

As of 6 Nov 2026, Poly Medicure trades at 51.4× trailing earnings, above the industry P/E of 28.6×, and the shares are 23% below their 52-week high. It earns ROCE of 13% and ROE of 10%, and sales and net profit grew 19% and 22% a year over 3 years. Its dividend yield is 0.2%, and debt is 0.12× equity. It is a small-cap company with a market cap of ₹16,343 Cr, ranked 3rd of 11 Medical Instruments & Supplies companies by market cap; the shares fell 18% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹1,602.20
Day high: ₹1,630.00
Day low: ₹1,542.40
Prev. close: ₹1,602.20
Volume: 1.4 L

Health check

1 good · 3 fair · 2 to check

ReturnsIn line
−18.1% over a year, better than 3 of 7 peers.
Price tagPricier
P/E 51.4 vs industry 28.6.
GrowthStrong
Sales +18.8%, profit +21.6% a year over 3 years.
ProfitabilityAverage
ROCE 13.3% vs peer median 11.5%.
Balance sheetFair
Debt 0.12× equity, interest covered 26.6×, Piotroski 5 of 9.
Red flags1 to check
P/E of 51.4 against an industry P/E of 28.6.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Medical Instruments & Supplies

10 listed peers. Screen the industry

Small cap

₹16,343 Cr, #3 of 11 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹2,110 Cr · profit ₹318 Cr

Market cap: ₹16,343 Cr; Small cap
P/E: 51.4; Industry 28.6
Price to book: 5.26; Peers 4.44
Dividend yield: 0.22%
ROE: 10.1%; Peers 10.5%
ROCE: 13.3%; Peers 11.5%
Debt to equity: 0.12; Debt ₹412 Cr
EPS (TTM): ₹31.37; Face value ₹5
OPM (TTM): 15.3%; Net margin 15.1%
Sales growth: +30.8%; Latest quarter vs a year ago
Profit growth: +3.6%; Latest quarter vs a year ago
Price to sales: 7.74; EV/EBITDA 34.8

Strengths

Quarterly sales up 30.8% on a year ago.
Positive operating cash flow in each of the last 4 years.

Risks to check

P/E of 51.4 against an industry P/E of 28.6.

Derived automatically from reported figures. Not a recommendation.

About Poly Medicure

Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, including I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial…

Headquarters: New Delhi
Employees: 2,614
Sector: Healthcare
ISIN: INE205C01021
Website: polymedicure.com

Price range

52 weeks

₹1,182.00₹2,094.30

Today

₹1,542.40₹1,630.00

Avg volume (3M): 1.5 L
1-year return: minus 18.1%
From 52-week high: minus 23.0%

Analyst consensus

6 analysts

No consensusMean target ₹1,858.17 15.2%

Target range, with today’s price

Low ₹1,528.00High ₹2,240.00

Consensus from Yahoo Finance. Not a recommendation.

Peers · Medical Instruments & Supplies

Compare with peers Screen the whole industry

Company
LENSKARTLenskart Solutions	724.75	plus 0.89%	1,25,562	160.7	13.48	7.2%	6.7%	20.8%	–	–	0.00%	plus 79.8%
AGARWALEYEDr. Agarwal's Health Care	516.35	plus 0.91%	16,373	94.1	7.66	9.7%	6.8%	15.0%	26.9%	12.3%	0.00%	minus 0.7%
POLYMEDPoly Medicure	1,612.30	plus 0.63%	16,343	51.4	5.26	13.3%	11.0%	15.2%	18.8%	21.6%	0.22%	minus 18.1%
TARSONSTarsons Products	316.95	minus 0.46%	1,686	151.7	2.64	4.8%	2.3%	−0.9%	14.3%	−43.8%	0.00%	plus 10.9%
LAXMIDENTLLaxmi Dental	196.42	minus 0.05%	1,081	34.8	4.44	11.5%	12.8%	16.4%	19.5%	–	0.00%	minus 37.9%
PREVESTPrevest Denpro	397.85	minus 3.85%	478	22.0	3.83	21.9%	17.8%	34.8%	12.4%	9.3%	0.25%	minus 21.2%
QMSMEDIQMS Medical Allied Services	168.66	minus 0.69%	326	28.6	5.68	18.4%	10.5%	12.0%	18.4%	16.7%	0.30%	plus 75.0%
SHREEPACShree Pacetronix	170.00	plus 0.32%	64	19.5	3.41	25.0%	19.7%	24.8%	2.2%	−1.2%	0.00%	minus 38.5%
Median of 7 peers	–	−0.05%	1,081	34.8	4.44	11.5%	10.5%	16.4%	16.4%	9.3%	0.00%	−0.7%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
444	494	535	525	581
329	539	424	400	443
115	−45.6	110	125	138
25.9%	−9.2%	20.7%	23.8%	23.7%
34.9	185	19.5	35	20.5
3	6	6.4	6.5	7.1
25	28.8	38.2	36.3	35
–	−6.8	–	–	9.6
122	97.6	85.2	117	125
24.6%	27.5%	23.7%	27.3%	24.2%
91.8	70.9	65	86	95.1
9.06	6.99	6.53	8.48	9.37

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +18.8%
Profit CAGR 3Y: +21.6%
EPS CAGR 3Y: +19.4%
ROE: 10.1%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
1,109	1,366	1,655	1,859
–	+23.2%	+21.2%	+12.4%
834	999	1,192	1,403
275	367	463	457
24.8%	26.8%	28.0%	24.6%
32.2	52.9	40.1	59.4
8.5	10.7	11.4	16.7
57.2	63.9	83.2	116
−4	−0.6	43.8	43.7
237	344	453	427
24.5%	25.0%	25.2%	25.0%
179	258	339	322
–	+44.1%	+31.1%	minus 4.8%
18.67	26.90	34.11	31.75

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
48	48	50.7	50.7
1,194	1,422	2,715	3,055
149	174	180	354
187	215	247	459
1,577	1,859	3,192	3,919
699	921	1,178	1,426
110	98.7	138	163
6.7	27.5	15	10.2
301	286	1,212	863
460	525	649	1,456
1,577	1,859	3,192	3,919

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
191	266	233	246
−179	−241	−1,187	−225
−12.5	−20.2	951	20.2
−0.7	5	−3.6	41.1
−239	−277	−331	−308
−48.2	−10.9	−98	−62
−24	−28.7	−30.3	−35.4

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 18.0% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you